$OBX

$OBX · Ale's World of Stocks · 2026-11-15

AI 摘要 · Ale's World of Stocks

Obsidian 是一项投机性早期投资,难以评估,若其旗舰药物无法上市,可能带来重大收益,也存在重大风险;其收入几乎为零,亏损达数亿美元,而已募集的 3.5 亿美元应足以支撑其运营至 2027 年试验结果出炉。说话者并未持有,将把它列入观察名单跟踪。

他说的是几年内
《Google is Betting $1.2B on These 5 Crashing Stocks 🚨》
Ale's World of Stocks发布 2026-11-15 · 12 段内容

播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策

01:20/ —打开原视频

逐段跳播

12 段内容
1:205:00

我们先从一家名为 Obsidian Therapeutics 的小型临床阶段生物技术公司说起,股票代码为 OBX。根据文件,Google 以约1,680万美元的投资将其纳入了自己的投资组合。

We begin with a small clinical-stage biotechnology company called Obsidian Therapeutics, ticker symbol OBX, which Google, according to documents, has added to its investment portfolio with an investment of approximately $16.8 million.

需要说明的是,这并不是 Google 突然决定在便宜的生物科技股上大肆挥霍。Obsidian 于8月通过与一家名为 Galera Therapeutics 的陷入困境的生物技术公司反向合并而上市,Google 的早期投资部门曾对后者进行过私募投资。这家公司的股份现已转换为公开股份。

To clarify, this is not a sudden decision by Google to day-splurge on cheap biotech stocks. Obsidian went public in August through a reverse merger with a struggling biotech company called Galera Therapeutics, in which Google’s early investment arm had a private investment.

That company whose shares have now been converted to public shares.

但如果我们看这张股票走势图,会发现公司自 IPO 以来的历程极其坎坷,股价下跌超过60%,市值降至不到8亿美元,这通常被认为属于小型企业类别。

But if we look at this stock chart, we will find that the company’s journey has been extremely rough since its IPO, with its stock value falling by more than 60%, bringing its market capitalization to less than $800 million, which is generally considered to be in the small business category.

但这家公司到底做什么?Obsidian 正在开发下一代细胞疗法,用于对抗晚期皮肤癌和肺癌等癌性肿瘤。这些治疗涉及从患者自身的肿瘤中提取免疫细胞,在实验室中进行改造,然后再注射回体内以消灭癌症。

But what exactly does this company do? Well, Obsidian is working on developing next-generation cell therapies to combat cancerous tumors such as advanced skin cancer and lung cancer.

These treatments involve taking immune cells from the patient's own tumor, engineering them in the laboratory, and then injecting them into the body to eliminate the cancer.

然而,目前这类或类似的细胞疗法存在一个重大问题:治疗后需要使用高剂量的有毒化学药物,不幸的是,这导致近四分之一的患者被送入重症监护室,甚至带有强烈的警告标识。

However, current cell therapies , such as these or similar ones, suffer from a major problem: they require high doses of toxic chemicals after treatment, unfortunately leading to nearly a quarter of patients being admitted to intensive care, and even carrying strong warnings.

但 Obsidian 的旗舰药物 Amso K cell 试图通过给细胞内置一个开关来解决这个问题,医生可以用一种 FDA 批准的简单口服药物来控制这个开关。理论上,这将消除有毒副作用,并让患者能够在门诊接受治疗。

But Obsidian's flagship drug, called Amso K cell, attempts to solve this problem by engineering cells with a built-in switch that doctors can control using a simple FDA-approved oral medication , which would, in theory, eliminate toxic side effects and allow patients to receive treatment on an outpatient basis.

在对常规治疗无反应的皮肤癌患者进行的第二阶段试验中,67%的患者对治疗有反应,且没有相关死亡。因此,一些华尔街分析师认为,一旦这款药物在未来取得重大成功,公司股价就有很大的上涨潜力。

In the second phase of their trials on skin cancer patients who had not responded to conventional treatments, 67% of them responded to the treatment with no associated deaths. For this reason, some Wall Street analysts see great potential for the company's stock to rise once this drug achieves significant success in the future.

然而,公司目前的财务数据仍然非常糟糕,Obsidian几乎没有任何收入,分析师预计到2028年也只有约800万美元,而在试图将旗舰药物推向市场的过程中,亏损仍高达数亿美元。

However, the company's financial data is still very bad at the moment, with Obsidian generating almost no revenue , and analysts predicting only about $8 million by 2028, with losses still in the hundreds of millions of dollars in its attempt to get its flagship drug to market.

但好消息是,他们最近新筹集了3.5亿美元资金,这将帮助他们撑过2027年重要的试验结果出炉。毫无疑问,像Google这样在生物技术领域拥有丰富经验和强大关系的巨头公司的支持,将帮助他们在临床阶段取得进一步进展。

But the good news is that they recently raised $350 million in new funding, which will help them get through their important trial results in 2027. There is no doubt that the support of a giant company like Google, which has extensive experience in the field of biotechnology and strong relationships, will help them make further progress in the clinical phases.

至于我,我希望任何致力于解决癌症最大难题的公司都能成功。但作为一项实际投资,在这个早期阶段很难评估他们,因为我认为这更像是一种投机,未来可能有大幅收益,但如果他们无法进入市场,也涉及重大风险。

As for me, I hope that any company that seeks to solve the biggest problems of cancer will succeed. But as an actual investment, it is difficult to evaluate them at this early stage, as I see it as more of a speculation, with the potential for significant future gains, but also involving significant risks if they cannot reach the market.

因此,这本质上是一项投机性投资。我个人不持有这家公司的股票,但我很高兴Google对它的支持让它成为我关注的重点,我很乐意把它加入我的观察名单,并在未来密切关注。

Therefore, it is a speculative investment by nature. I personally do not own shares in this company, but I am glad that Google’s support for it has made it a focus of my attention, and I will gladly add it to my watchlist and follow it closely in the future.

至于它的排名,我暂时把它放在第三位,等我们看到这份名单上的其他名字后,再作修改。

As for its ranking, I will temporarily place it in third place, until we see the other names on this list, then we can modify it later .

观察点

公司旗舰药物重要临床试验的结果
临床试验结果成功
2027年公司临床试验结果
支持未来大幅上涨的潜力
跨洋听风